Project Grant R01CA287114
Award Date
8/7/24
Completion Date
7/31/29
Dollars Obligated
$675K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $268,345 to the Sanford Burnham Prebys Medical Discovery Institute to develop a novel immunotherapy for pancreatic cancer. The goal is to investigate the therapeutic potential of blocking the PSGL-1/VISTA axis, which regulates T cell function, to enhance the immune response against pancreatic tumors. The research will explore the impact of PSGL-1 blockade alone and in combination with...
This Project Grant award of $673,526 from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports research at the University of Pittsburgh to investigate the mechanistic role of p16 loss in regulating zinc homeostasis through the zinc transporter SLC39A9 and its impact on the efficacy of immune checkpoint blockade therapy in melanoma. The research aims to explore whether manipulating zinc levels can enhance the effectiveness of current immune...
This $103,948 Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to the Sloan-Kettering Institute for Cancer Research supports research aimed at elucidating the mechanisms driving T-cell dysfunction within the tumor microenvironment. The research plan includes two main components: Predoctoral research (Aim 1) to investigate how local amino acid availability limits effector function in tumor-infiltrating T-cells, including profiling the...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) in the amount of $121,857 aims to systematically investigate how anti-cancer drugs modulate T cells in the tumor microenvironment. The key objectives are to: Conduct in silico screening to identify anti-cancer drugs impacting T cell effector function, activation, stemness, and proliferation (Aim I). Perform single-cell CRISPR knockout screening to determine anti-cancer drug targets...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,419,108 to Emory University to advance the understanding of how a novel neoadjuvant therapy impacts the immune system in patients with solid tumors, using refractory melanoma as a model. The award will fund research to gain insights into how blocking the SEMA4D signaling pathway, when combined with immune checkpoint blockade, enhances the activity of antigen-presenting dendritic...
This federal Project Grant award of $532,970.00, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to define the key cell-intrinsic features and cell interactions of anti-tumor CD4 T cells that promote anti-tumor immunity and enhance responses to PD-1 targeted immunotherapy. The 5-year project, awarded to the Icahn School of Medicine at Mount Sinai, aims to study the transcriptional programs and secreted factors in...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides funding of $695,916 to The Regents of the University of California, San Francisco (UCSF) to evaluate and optimize novel inhibitors of the NSMASE2 enzyme for enhancing the effectiveness of immune checkpoint inhibitors in cancer treatment. The project aims to synthesize and test PDDC analogs to improve the potency, solubility, and pharmacokinetics of NSMASE2 inhibitors. Promising...
This federal Project Grant award of $269,280 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to determine the biological effects and antitumor activity of a senescent cell-targeted antibody, SIWA318, in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The research aims to evaluate whether depletion of senescent and pro-fibrotic cells in the PDAC tumor microenvironment can improve the efficacy of standard-of-care...
This Project Grant award of $577,818 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new effective therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers treated with radiotherapy. The funded research project will: 1) Dissect the mechanisms by which the immune checkpoint molecule B7-H3 impairs CD8 T cell cytotoxicity, using proximity labeling technologies and mouse models, and...